0001933414-24-000034.txt : 20240712
0001933414-24-000034.hdr.sgml : 20240712
20240712163759
ACCESSION NUMBER: 0001933414-24-000034
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240711
FILED AS OF DATE: 20240712
DATE AS OF CHANGE: 20240712
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Levy Adam Scott
CENTRAL INDEX KEY: 0001693134
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-41614
FILM NUMBER: 241114956
MAIL ADDRESS:
STREET 1: C/O MIRAGEN THERAPEUTICS, INC.
STREET 2: 6200 LOOKOUT ROAD, #100
CITY: BOULDER
STATE: CO
ZIP: 80301
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Mineralys Therapeutics, Inc.
CENTRAL INDEX KEY: 0001933414
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 150 N. RADNOR CHESTER ROAD
STREET 2: SUITE F200
CITY: RADNOR
STATE: PA
ZIP: 19087
BUSINESS PHONE: (888) 378-6240
MAIL ADDRESS:
STREET 1: 150 N. RADNOR CHESTER ROAD
STREET 2: SUITE F200
CITY: RADNOR
STATE: PA
ZIP: 19087
4
1
wk-form4_1720816673.xml
FORM 4
X0508
4
2024-07-11
0
0001933414
Mineralys Therapeutics, Inc.
MLYS
0001693134
Levy Adam Scott
150 N. RADNOR CHESTER ROAD,
SUITE F200
RADNOR
PA
19087
0
1
0
0
CFO and Secretary
1
Common Stock
2024-07-11
4
S
0
10757
13.1444
D
247611
D
The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 14, 2023.
The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $12.93 to $13.43. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4.
This balance includes 2,906 shares purchased under the Mineralys Therapeutics, Inc. 2023 Employee Stock Purchase Plan that were not previously reported.
/s/ Adam Levy
2024-07-12